An Open Label, Multi-Center Phase 1b/2a Trial Investigating Different Doses of Sym004 in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer Progressing After First Line Therapy

Trial Profile

An Open Label, Multi-Center Phase 1b/2a Trial Investigating Different Doses of Sym004 in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer Progressing After First Line Therapy

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 13 Jul 2018

At a glance

  • Drugs Futuximab/modotuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Symphogen
  • Most Recent Events

    • 06 Jun 2018 Status changed from active, no longer recruiting to discontinued.
    • 26 Dec 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 23 Jun 2017 Planned End Date changed from 1 Jun 2018 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top